Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Accounts Payables (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Accounts Payables for 7 consecutive years, with $22.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 584.04% year-over-year to $22.2 million, compared with a TTM value of $22.2 million through Sep 2025, up 584.04%, and an annual FY2024 reading of $4.6 million, up 73.83% over the prior year.
  • Accounts Payables was $22.2 million for Q3 2025 at Summit Therapeutics, down from $23.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $23.0 million in Q2 2025 and bottomed at $355000.0 in Q4 2022.
  • Average Accounts Payables over 5 years is $5.7 million, with a median of $4.1 million recorded in 2021.
  • The sharpest move saw Accounts Payables crashed 91.88% in 2022, then skyrocketed 797.32% in 2024.
  • Year by year, Accounts Payables stood at $4.4 million in 2021, then plummeted by 91.88% to $355000.0 in 2022, then soared by 651.27% to $2.7 million in 2023, then skyrocketed by 73.83% to $4.6 million in 2024, then surged by 379.83% to $22.2 million in 2025.
  • Business Quant data shows Accounts Payables for SMMT at $22.2 million in Q3 2025, $23.0 million in Q2 2025, and $5.0 million in Q1 2025.